Clinical Trial Detail

NCT ID NCT02041481
Title MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors City of Hope Medical Center, National Cancer Institute (NCI), Novartis
Indications

colorectal cancer

rectum cancer

colon cancer

Therapies

Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin

Age Groups: adult

No variant requirements are available.